Surgical debulking of gastrointestinal stromal tumors: Is it a reasonable option after second-line treatment with sunitinib?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
After imatinib treatment, the surgical management of patients affected by gastrointestinal stromal tumor (GIST) has been widely reported and often considered by many oncologists in clinical practice. Surgical results are correlated with disease responsiveness to tyrosine kinase inhibitors and with complete extirpation of all tumor sites. By now, no report specifically addressing surgical management after second-line treatment with sunitinib is still available. Most patients have an unresectable disease and do not have any other therapeutical options except for clinical trials.
Materials and methods
We report two clinical cases of patients with metastatic GISTs, who underwent surgery after sunitinib, and discuss the surgical management option in this clinical setting.
Both our patients had a long, durable stable disease on sunitinib, but one developed a chronic mild bleeding that does not call for emergency surgical interventions and the other one developed chronic heart toxicity. They were proposed to undergo surgery despite the unresectable diseases and received an incomplete resection because of residual metastatic lesions. They restarted sunitinib after surgery.
The poor prognosis after sunitinib treatment and the absence of alternative validated options open the debate on the assessment of surgical management of metastatic GISTs in this setting. The role of surgery should be investigated in clinical trials; however, the enrollment may be difficult. In clinical practice and after a multidisciplinary case patient discussion, surgery could represent a reasonable choice for advanced GISTs especially if the risk of surgery-related death is not too high.
- Andersson, J, Bümming, P, Meis-Kindblom, JM, Sihto, H, Nupponen, N, Joensuu, H, Odén, A, Gustavsson, B, Kindblom, LG, Nilsson, B (2006) Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130: pp. 1573-1581 CrossRef
- Andtbacka, RH, Ng, CS, Scaife, CL, Cormier, JN, Hunt, KK, Pisters, PW, Pollock, RE, Benjamin, RS, Burgess, MA, Chen, LL, Trent, J, Patel, SR, Raymond, K, Feig, BW (2007) Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 14: pp. 14-24 CrossRef
- Antonescu, CR, Besmer, P, Guo, T, Arkun, K, Hom, G, Koryotowski, B, Leversha, MA, Jeffrey, PD, Desantis, D, Singer, S, Brennan, MF, Maki, RG, DeMatteo, RP (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: pp. 4182-4190 CrossRef
- Benjamin, RS, Blanke, CD, Blay, JY, Bonvalot, S, Eisenberg, B (2006) Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist 11: pp. 9-20 CrossRef
- Bonvalot, S, Eldweny, H, Pechoux, CL, Vanel, D, Terrier, P, Cavalcanti, A, Robert, C, Lassau, N, Cesne, AL (2006) Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 13: pp. 1596-1603 CrossRef
- DeMatteo, RP, Lewis, JJ, Leung, D, Mudan, SS, Woodruff, JM, Brennan, MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231: pp. 51-58 CrossRef
- DeMatteo, RP, Maki, RG, Singer, S, Gonene, M, Brennan, MF, Antonescu, CR (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245: pp. 347-352 CrossRef
- Demetri, GD, Mehren, M, Blanke, CD, Abbeele, AD, Eisenberg, B, Roberts, PJ, Heinrich, MC, Tuveson, DA, Singer, S, Janiceck, M, Fletcher, JA, Silverman, SG, Silberman, SL, Capdeville, R, Kiese, B, Peng, B, Dimitrijevic, S, Druker, BJ, Corless, C, Fletcher, CD, Joensuu, H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: pp. 472-480 CrossRef
- Demetri, GD, Oosterom, AT, Garrett, CR, Blackstein, ME, Shah, MH, Verweij, J, McArthur, G, Judson, IR, Heinrich, MC, Morgan, JA, Desai, J, Fletcher, CD, George, S, Bello, CL, Huang, X, Baum, CM, Casali, PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: pp. 1329-1338 CrossRef
- Gronchi, A, Fiore, M, Miselli, F, Lagonigro, MS, Coco, P, Messina, A, Pillotti, S, Casali, PG (2007) Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245: pp. 341-346 CrossRef
- Haller, F, Dekten, S, Schulten, H-J, Happel, N, Gunawan, B, Kuhlgatz, J, Fuzesi, L (2007) Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumors (GIST) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 14: pp. 526-532 CrossRef
- Heinrich, MC, Corless, CL, Demetri, GD, Balnke, CD, Mehren, M, Joensuu, H, McGreevey, LS, Chen, CJ, Abbeele, AD, Druker, BJ, Kiese, B, Eisenberg, B, Roberts, PJ, Singer, S, Fletcher, CD, Silkerman, S, Dimitrijevic, S, Fletcher, JA (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: pp. 4342-4349 CrossRef
- Jamali, FK, Drawiche, SS, El-Kinge, N, Tawil, A, Soweid, AM (2007) Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy. Oncologist 12: pp. 438-442 CrossRef
- Lux, ML, Rubin, BP, Biase, TL, Chen, CJ, Maclure, T, Demetri, G, Xiao, S, Singer, S, Fletcher, CD, Fletcher, JA (2000) KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156: pp. 791-795
- Nilsson, B, Bumming, P, Meis-Kindblom, JM, Oden, A, Dortok, A, Gustavsson, B, Sablinska, K, Kindblom, LG (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer 103: pp. 821-829 CrossRef
- Ozguc, H, Yilmazlar, T, Yerci, O, Soylu, R, Tumay, V, Filiz, G, Zorluoglu, A (2005) Analysis of prognostic and immunohistochemical factors in gastrointestinal stromal tumors with malignant potential. J Gastrointest Surg 9: pp. 418-429 CrossRef
- Pierie, JP, Choudry, U, Muzikansky, A, Yeap, BY, Souba, WW, Ott, MJ (2001) The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136: pp. 383-389 CrossRef
- Raut, CP, Posner, M, Desai, J, Morgan, JA, George, S, Zahrieh, G, Fletcher, CD, Demetri, GD, Bertagnolli, MM (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24: pp. 2325-2331 CrossRef
- Rutkowski, P, Nowecki, Z, Nyckowski, P, Dziewirski, W, Grzesiakowska, U, Naisierowska-Guttmejer, A, Krawczyck, M, Ruka, W (2006) Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 93: pp. 304-311 CrossRef
- Scaife, CL, Hunt, KK, Patel, SR, Benjamin, RS, Benjamin, RS, Burgess, MA, Chen, LL, Trent, J, Raymond, AK, Cormier, JN, Pisters, PW, Pollock, RE, Feig, BW (2003) Is there a role for surgery in patients with unresectable cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg 186: pp. 665-669 CrossRef
- Tamborini, E, Bonadiman, L, Greco, A, Albertini, V, Neri, T, Gronchi, A, Bertulli, R, Colecchia, M, Casali, PG, Pierotti, MA, Pilotti, S (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127: pp. 294-299 CrossRef
- Verweij, J, Casali, PG, Zalcberg, J, LeCesne, A, Reichardt, P, Blay, YJ, Issels, R, Oosterom, A, Hogendoorn, PC, Glabbeke, M, Bertulli, R, Judson, I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: pp. 1127-1134 CrossRef
- Wu, PC, Langerman, A, Ryan, CW, Hart, J, Swiger, S, Posner, MC (2003) Surgical treatment of gastrointestinal stromal tumors in the imatinib era. Surgery 134: pp. 665-666 CrossRef
- Surgical debulking of gastrointestinal stromal tumors: Is it a reasonable option after second-line treatment with sunitinib?
Journal of Cancer Research and Clinical Oncology
Volume 134, Issue 5 , pp 625-630
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Gastrointestinal stromal tumors
- TK inhibitors
- Industry Sectors
- Author Affiliations
- 1. Institute of Hematology and Medical Oncology “L. A. Seragnoli”, Sant’ Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40126, Bologna, Italy
- 2. Emergency Surgery and Transplant Department, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
- 3. Department of Radiology, Sant’ Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
- 4. Department of Pathology, Sant’ Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
- 5. Centre of Applied Biomedical Research (CRBA), Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
- 6. Nuclear Medicine Service, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy